Stakeholders' perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: A mixed methods study

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Van Der Putten, Ingeborg M ^a,b   Evers, Silvia M A A ^a   Deogaonkar, Rohan ^c   Jit, Mark ^c,d   Hutubessy, Raymond C W ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Decision making; Developing countries; Economic evaluations; Externalities; Immunization; Low and middle income countries; Mixed methods; Vaccines

Indexed keywords

VACCINE;

COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION MAKING; ECONOMICS; FEMALE; HUMAN; PERCEPTION; PREVENTIVE HEALTH SERVICE; VACCINATION;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; PERCEPTION; VACCINATION; VACCINES;

EID: 84949121220     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-1638-0     Document Type: Article

References (36)

1. Global Health Observatory. Under five mortality. http://www.who.int/gho/child-health/mortality/mortality-under-five-text/en/index.html.
2. Save the Children Fund. No child born to die: closing the gaps. London: Save the Children UK; 2011.
3. GAVI Alliance. Investing in immunisation through the GAVI Alliance; the evidence base. Geneva: GAVI Alliance; 2010.
4. Hauck K, Smith PC, Goddard M. The economics of priority setting for health care: a literature review. The International Bank for Reconstruction and Development/The World Bank. 2003;10:03-8.
5. Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics. 2009;27(10):861-72.
6. Jauregui B, Sinha A, Clark AD, Bolanos BM, Resch S, Toscano CM, et al. Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: lessons learned by PAHO's ProVac Initiative. Vaccine. 2011;29(5):1099-106.
7. WHO. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring. Geneva; Switzerland; 2014.
8. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine. 2005;23(19):2470-6.
9. Kimman TG, Boot HJ, Berbers GAM, Vermeer-de Bondt PE, de Ardine Wit G, de Melker HE. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine. 2006;24(22):4769-78.
10. Mansoor O, Shin S, Maher C. WPRO tIFo: assessing new vaccines for national immunization programmes. A framework to assist decision makers. Manila: World Health Organization Regional Office for the Western Pacific Manila; 2000.
11. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century: a tool for decisionmaking, Committee to Study Priorities for Vaccine Development. Division of Health Promotion and Disease Prevention, Institute of Medicine. Washington, DC: National Academy of Sciences; 1999.
12. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010;28(11):2356-9.
13. Piso B, Wild C. Decision support in vaccination policies. Vaccine. 2009;27(43):5923-8.
14. Bärnighausen T, Bloom DE, Canning D, Friedman A, Levine OS, O'Brien J, et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. Vaccine. 2011;29(13):2371-80.
15. Bloom DE, Canning D, Weston M. The value of vaccination. World Econ. 2005;6(3):15.
16. Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS. Cost-effectiveness and economic benefits of vaccines in low-and middle-income countries: a systematic review. Vaccine. 2012;31(1):96-108.
17. Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health. 2012;12(1):878.
18. Bärnighausen T, Bloom DE, Cafiero-Fonseca ET, O'Brien JC. Valuing vaccination. Proc Natl Acad Sci. 2014;111(34):12313-9.
19. Belli PC, Bustreo F, Preker A. Investing in children's health: what are the economic benefits? Bull World Health Organ. 2005;83(10):777-84.
20. Burns JE, Mitrovich RC, Jauregui B, Ruiz Matus C, Andrus JK. Descriptive analysis of immunization policy decision making in the Americas. Rev Panam Salud Publica. 2009;26(5):398-404.
21. Culyer AJ, Newhouse JP. Handbook of health economics, volume 1. A. Amsterdam: North Holland; 2000.
22. Bärnighausen T, Bloom DE, Canning D, O'Brien J. Accounting for the full benefits of childhood vaccination in South Africa. S Afr Med J. 2008;98(11):842.
23. Banerji D. Serious crisis in the practice of International health by the World Health Organization: the Commission on Social Determinants of Health. Int J Health Serv. 2006;36(4):637-50.
24. Beutels P, Thiry N, Van Damme P. Convincing or confusing?: Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine. 2007;25(8):1355-67.
25. Shearley AE. The societal value of vaccination in developing countries. Vaccine. 1999;17:S109-12.
26. Swine Flu Prompts A World Of Different Reactions. http://www.npr.org/templates/story/story.php?storyId=103614016.
27. Dickson R, Awasthi S, Williamson P, Demellweek C, Garner P. Effects of treatment for intestinal helminth infection on growth and cognitive performance in children: systematic review of randomised trials. BMJ. 2000;320(7251):1697-701.
28. Sakti H, Nokes C, Hertanto W, Hendratno S, Hall A, Bundy DAP. Evidence for an association between hookworm infection and cognitive function in Indonesian school children. Trop Med Int Health. 1999;4(5):322-34.
29. Creswell JW, Clark VLP. Designing and conducting mixed methods research. Allen & Unwin: Sydney; 2007.
30. Bank W. World Bank list of economies 18 july 2011. 2011.
31. Duclos P, Ortynsky S, Abeysinghe N, Cakmak N, Janusz CB, Jauregui B, et al. Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups. Vaccine. 2012;30(50):7147-52.
32. Burchett H, Mounier-Jack S, Griffiths U, Biellik R, Ongolo-Zogo P, Chavez E, et al. New vaccine adoption: qualitative study of national decision-making processes in seven low-and middle-income countries. Health Policy Plan. 2012;27 suppl 2:ii5-16.
33. Bloom DE, Canning D, Shenoy ES. The effect of vaccination on children's physical and cognitive development in the Philippines. Appl Econ. 2012;44(21):2777-83.
34. Beutels P, Edmunds WJ, Smith RD. Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. Health Econ. 2008;17(11):1317-22.
35. Dawis RV. Scale construction. J Couns Psychol. 1987;34(4):481.
36. Ryan M, Scott D, Reeves C, Bate A, Van Teijlingen E, Russell E, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health technol. Assess 2001;5(5).